T1 efficacy of EVP-ABD: a potential manganese-based MR contrast agent for hepatic vascular and tissue phase imaging.
T1 efficacy of EVP-ABD: a potential manganese-based MR contrast agent for hepatic vascular and tissue phase imaging.
复制标题
EVP-ABD 的 T1 功效：一种用于肝血管和组织阶段成像的潜在锰基 MR 造影剂。
DOI：
10.1002/jmri.10203
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
Rofsky,NM
中科院分区：
文献类型：
--
作者：
Zuo,CS;Seoane,P;Lanigan,T;Harnish,P;Prasad,PV;Storey,P;Li,W;Rofsky,NM
PurposeTo evaluate T1 efficacy of EVP‐ABD，a new manganese（Mn）‐based contrast agent，for vascular and liver tissue enhancement in comparison with currently approved agents.Materials and Methods 10只约克郡猪（体重26 - 46 kg）用于疗效评价，9只用于动力学T1评价（每种药物3只），1只用于EVP‐ABD后成像。采用快速成像方案监测血液和肝脏的T1值，静脉注射10 μmol/kg EVP‐ABD，并与常规临床剂量的钆喷酸葡胺（Magnevist®，GdDTPA）和锰福地吡三钠（Teslascan®，锰福地吡三钠）进行比较。在注射前和注射后10分钟，使用1.5-T全身扫描仪，使用3D T1梯度回波（GRE）序列（TR/TE/α = 3.8/1.6/25°）对所有患者进行成像。额外的高分辨率二维肝脏图像（TR/TE/α = 50/4.6/40°）和动脉相图像的上主动脉从猪后EVP-ABD imaging.ResultsAt 10 μmol/kg，EVP-ABD提供了一个显着下降的血液T1，相当于0.1 mmol/kg GdDTPA，随后迅速返回到血液基线T1值。除了血液增强阶段，EVP‐ABD在给药后2分钟内实现了肝脏T1降低70%，成像窗口至少为2小时。在2D和3D肝脏图像postcontrast.ConclusionEVP‐ABD表现出类似于GdDTPA的峰值血管增强和超过mangafodipir三钠的长期特异性肝脏增强，观察到一个显着改善的信号噪声比（SNR）。EVP‐ABD具有良好的T1增强特征，有可能进行全面的肝脏评价。J.磁共振成像2002;16：668-675.© 2002 Wiley利斯公司
PurposeTo evaluate the T1 efficacy of EVP‐ABD, a new manganese (Mn)‐based contrast agent, for vascular and liver tissue enhancement in comparison with currently approved agents.Materials and MethodsTen Yorkshire pigs (body weight, 26 –46 kg) were used for the efficacy evaluation, nine for kinetic T1 evaluation (three each agent) and one for post EVP‐ABD imaging. With a fast imaging scheme to monitor T1 values of blood and liver, 10 μmol/kg EVP‐ABD was injected intravenously and compared with gadopentetate dimeglumine (Magnevist®, GdDTPA) and mangafodipir trisodium (Teslascan®, mangafodipir trisodium) at routine clinical dosages. All were imaged with 3D T1 Gradient Recalled Echo (GRE) sequence (TR/TE/α = 3.8/1.6/25°) prior to and 10 minutes post injection using a 1.5‐T whole‐body scanner. Additional high‐resolution 2D liver images (TR/TE/α = 50/4.6/40°) and arterial phase images of the upper aorta were acquired from the pig for post EVP‐ABD imaging.ResultsAt 10 μmol/kg, EVP‐ABD provided a dramatic decline in blood T1, comparable to 0.1 mmol/kg GdDTPA, followed by a rapid return to blood baseline T1 values. In addition to the blood enhancement phase, EVP‐ABD achieved a 70% reduction in liver T1 within 2 minutes postadministration, with an imaging window of at least 2 hours. A substantially improved signal‐to‐noise ratio (SNR) was observed in both the 2D and 3D liver images postcontrast.ConclusionEVP‐ABD demonstrated peak vascular enhancement similar to GdDTPA and prolonged specific liver enhancement exceeding mangafodipir trisodium. EVP‐ABD has favorable T1 enhancing characteristics with the potential to allow for a comprehensive liver evaluation. J. Magn. Reson. Imaging 2002;16:668–675. © 2002 Wiley‐Liss, Inc.